Choose a language and wait for the translated text.
The US giant acquired nemtabrutinib, a selective BTK inhibitor, under its $2.7 billion takeover of ArQule after paying a hefty 100 per cent premium at $20 per share for the Nasdaq-listed company.
Merck scraps $2.7 bn Blood cancer buyout nemtabrutinib after risk-return assessment | PharmaVoice